Cuba teams with China's Lukang to manufacture biotech products; Catalent, BASF take on solubility challenges;

> Cuba's Center for Genetic Engineering and Biotechnology and Lukang Pharmaceutical in China announced plans to cooperatively manufacture and market biotechnology products. Item

> Catalent and BASF will jointly market technology to address drug solubility issues to help companies formulate optimal dose form from development through scale-up and supply. Story

> Nepal's Department of Drug Administration is writing good manufacturing practice (GMP) regulations that will meet World Health Organization (WHO) standards in expectation of raising drug manufacturing standards and making the country's pharmaceuticals more acceptable internationally. Article

> US Pharmacopeia (USP) is investing $1.5 million and looking for donors to set up a facility which will fund itself offering quality control services to pharmaceutical manufacturers in Sub-Saharan Africa. Story

> Omkar Specialty Chemicals in India has acquired LASA Laboratory, which has an API manufacturing facility that makes mostly active ingredients for veterinary pharmaceuticals. More

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.